Tag: JNJ
-
JNJ Stock Slips Despite Beat and Raised Guidance
Johnson & Johnson delivered another solid quarter, beating expectations on both revenue and earnings while raising full-year guidance. However, the stock slipped in early trading as investors reacted to broader market weakness and an FDA warning for one of the company’s key oncology drugs, Carvykti. Despite the pullback, JNJ stock is up 32% in 2025…